<a href="https://laohu8.com/S/ASND">Ascendis Pharma A/S</a> Presents Interim Results from COACH Trial on Achondroplasia Treatment
Ascendis Pharma A/S has released interim topline data from their Phase 2 COACH Trial, which is evaluating the combination treatment of TransCon CNP and TransCon hGH in children with achondroplasia. The Week 26 data revealed that in the TransCon CNP treatment-naïve cohort, the mean annualized growth velocity (AGV) was 9.14 cm/year, with an improvement in the mean ACH height Z-score of +0.53 over the 26 weeks. For the cohort previously treated with TransCon CNP, the mean AGV was 8.25 cm/year, with a +0.44 improvement in the mean ACH height Z-score over 26 weeks. The trial aims to assess the effect of the combination treatment on linear growth compared to TransCon CNP alone. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on June 09, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。